Digi International Expands Industry-Leading Portfolio of Connectivity Solutions for Private Cellular Networks, Supporting Transmission and Distribution for Utilities
7.2.2023 16:00:00 EET | Business Wire | Press release
Expanding its portfolio of solutions to support private cellular networks, Digi International (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched new versions of its widely adopted Digi IX10 cellular router at DistribuTECH 2023. The new solution enables electric utilities to deploy private cellular networks that leverage the CBRS Band 48 shared spectrum or Anterix Band 8 900 MHz licensed spectrum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005387/en/
Digi supports private networks in collaboration with third-party providers. (Photo: Business Wire)
Building upon its expansive portfolio of Private Cellular Network (PCN) enabled devices, Digi IX10 is a full-featured cellular router combining trouble-free reliability with long service life. Flexible power and connectivity options make it a versatile and cost-effective choice for electric utilities, smart-grid equipment manufacturers, and other stakeholders that need to secure critical infrastructure data transmission over private cellular networks — including variants for Anterix 900 MHz licensed spectrum and CBRS 3.5 GHz spectrum.
“In the utilities market, private broadband is rapidly emerging as a must-have for grid modernization efforts,” said Carlos L'Abbate, CTO from Anterix. “As the nation’s largest holder of licensed spectrum in the 900 MHz band, our Anterix Active Ecosystem welcomes Digi’s latest addition to its portfolio of PCN-enabled routers. Together, Digi and Anterix are uniquely positioned to help utilities achieve secure, resilient and customer-controlled operations.”
The new Digi solution is ideal for a range of use cases in the industrial and utilities sectors, including transmission and distribution automation, connecting grid assets, metering, power quality monitoring, and remote instrumentation, as well as EV charging, solar farms, and other utilities applications that require greater intelligence, visibility, and edge computing.
“When it comes to modernizing our grid infrastructure, connectivity remains among the most important requirements,” said Kinana Hussain, Vice President of Product Management, from Digi International. “The latest model of the Digi IX10 expands our PCN device portfolio and, coupled with Digi Remote Manager, reaffirms our commitment to providing the smart and affordable connectivity needed by stakeholders in the electric utilities industry.”
Digi’s PCN solutions feature Digi Remote Manager® (Digi RM), the command center enabling the orchestration, management, and visibility of PCN devices. Digi RM enables low/no-touch provisioning, mass configuration, maintenance, and support, even for thousands of devices. With Digi RM, utilities can evaluate, update, and configure Digi devices while gaining visibility into network health. Digi also offers an on-premise remote management option for deployments requiring full control, and customization of their networking infrastructure.
“Digi International has been a prominent member of the OnGo Alliance for many years,” said Alan Ewing, Executive Director of the OnGo Alliance. “The launch of the Digi IX10 for CBRS marks another milestone in the continued adoption of 4G LTE and 5G solutions using shared spectrum. This addition to the company’s broad portfolio of PCN solutions will offer utilities – and other companies as well – more deployment options as they strive to improve the resiliency of the nation’s grid infrastructure.”
IX10 Features & Benefits:
-
Design – Compact, economical and rugged, Digi IX10’s small footprint provides versatility in placement, and its specs ensure it can withstand broad temperature ranges, making it ideal for public or private cellular networks in harsh environments.
-
Flexibility – Wirelessly connects IP-based devices while protecting investments in legacy serial devices. Flexible power input and low-power consumption allows it to use existing DC power in control cabinets, as well as solar for remote installations.
-
Reliability – Redundant connectivity with dual SIMs and Digi SureLink® for failover from private to public networks, or dual-public networks.
- Security - Built-in Digi TrustFence® for device security, device identity and data privacy.
For pricing information, contact Digi International.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005387/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
